Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 1
2005 2
2007 5
2008 5
2009 2
2010 3
2011 6
2012 3
2013 5
2014 3
2015 4
2016 6
2017 4
2018 8
2019 4
2020 7
2021 3
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Larroquette M, et al. Among authors: le moulec s. J Immunother Cancer. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. J Immunother Cancer. 2022. PMID: 35618288 Free PMC article.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, Goldberg SB, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Rizvi NA, et al. Among authors: le moulec s. JAMA Oncol. 2020 May 1;6(5):661-674. doi: 10.1001/jamaoncol.2020.0237. JAMA Oncol. 2020. PMID: 32271377 Free PMC article. Clinical Trial.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. Among authors: le moulec s. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, Carbone DP. Morgensztern D, et al. Among authors: le moulec s. Clin Cancer Res. 2019 Dec 1;25(23):6958-6966. doi: 10.1158/1078-0432.CCR-19-1133. Epub 2019 Sep 10. Clin Cancer Res. 2019. PMID: 31506387 Free PMC article. Clinical Trial.
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA. Zauderer MG, et al. Among authors: le moulec s. Lancet Oncol. 2022 Jun;23(6):758-767. doi: 10.1016/S1470-2045(22)00277-7. Epub 2022 May 16. Lancet Oncol. 2022. PMID: 35588752 Clinical Trial.
[Craniopharyngiomas: role of radiotherapy].
Chargari C, Bauduceau O, Bauduceau B, Camparo P, Ceccaldi B, Fayolle M, Le Moulec S, Védrine L. Chargari C, et al. Among authors: le moulec s. Bull Cancer. 2007 Nov;94(11):987-94. Bull Cancer. 2007. PMID: 18055317 Free article. Review. French.
[Cell cycle and molecular targets: CDK inhibition].
Carassou P, Meijer L, Le Moulec S, Aoun J, Bengrine-Lefèvre L. Carassou P, et al. Among authors: le moulec s. Bull Cancer. 2012 Feb 1;99(2):163-71. doi: 10.1684/bdc.2011.1383. Bull Cancer. 2012. PMID: 21737380 Free article. Review. French.
Whole-brain radiation therapy in breast cancer patients with brain metastases.
Chargari C, Campana F, Pierga JY, Védrine L, Ricard D, Le Moulec S, Fourquet A, Kirova YM. Chargari C, et al. Among authors: le moulec s. Nat Rev Clin Oncol. 2010 Nov;7(11):632-40. doi: 10.1038/nrclinonc.2010.119. Epub 2010 Jul 13. Nat Rev Clin Oncol. 2010. PMID: 20625374 Review.
Reapprasial of the role of endocrine therapy in meningioma management.
Chargari C, Védrine L, Bauduceau O, Le Moulec S, Ceccaldi B, Magné N. Chargari C, et al. Among authors: le moulec s. Endocr Relat Cancer. 2008 Dec;15(4):931-41. doi: 10.1677/ERC-08-0083. Epub 2008 Jul 16. Endocr Relat Cancer. 2008. PMID: 18632875 Review.
74 results